https://doi.org/10.55788/236b8e48
The combination of talazoparib plus temozolomide reached the primary efficacy endpoint in a phase 2 study that tested this combination therapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Since the safety profile was manageable, a phase 3 study is appropriate to confirm the clinical benefits of this treatment [1].
The current phase 2 trial (NCT03672773) evaluated the efficacy of the PARP inhibitor talazoparib in combination with temozolomide in 28 patients with relapsed or refractory ES-SCLC. Dr Jonathan Goldman (David Geffen School of Medicine at UCLA, CA, USA) presented the findings. An objective response rate (ORR) of 29% was needed to meet the primary endpoint.
The ORR was 39.3%, representing 11 patients with partial responses. The median time to response was 1.8 months, and the median duration of response was 4.3 months. In addition, the progression-free survival was 4.3 months and the overall survival was 11.9 months.
Haematologic adverse events (AEs) were commonly observed in this patient population. A total of 53.6%, 32.1%, and 60.7% of the participants experienced grade 3 or 4 anaemia, decreased neutrophil count, or decreased platelet count, respectively. The most frequently observed non-haematologic AEs were fatigue, nausea, diarrhoea, and anorexia, predominantly being grade 1 or 2 events. Dr Goldman mentioned that exploratory results are currently being investigated. “This is the second study to demonstrate the clinical benefits of a PARP inhibitor in combination with temozolomide in patients with SCLC,” added Dr Goldman [2]. “Therefore, a phase 3 trial is appropriate to confirm the safety and efficacy of this combination regimen in SCLC.”
- Goldman J, et al. Phase 2 study analysis of talazoparib plus temozolomide for extensive-stage small cell lung cancer (ES-SCLC). OA12.03, WCLC 2022, Vienna, Austria, 06–09 August.
- Farago AF, et al. Cancer Discov. 2019 Oct;9(10):1372-1387.
Copyright ©2022 Medicom Medical Publishers
Posted on
« Pembrolizumab plus lenvatinib performs well in MPM Next Article
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC »
Table of Contents: WCLC 2022
Featured articles
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
WCLC 2022 Congress Round-Up
Sugemalimab offers PFS benefits for unresectable NSCLC
First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
NADIM: Risk of progression identified through RNA sequencing
NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?
First DLL3-targeted therapy shows promise in SCLC
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Pembrolizumab plus lenvatinib performs well in MPM
Early detection strategies in younger patients with lung cancer are urgently needed
Intensive co-located smoking cessation programme highly effective during lung screening
Do we underestimate the effect of air pollution on lung cancer incidence?
Interventions needed to address sexual health in lung cancer
Related Articles

Liquid biopsy to decide the best treatment for NSCLC
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy